| 2025-04-24 | +1.52 % |
|
| 2025-04-23 | +0.94 % |
|
| 2025-04-22 | +1.45 % |
|
| 2025-04-21 | -1.02 % |
|
| 2025-04-17 | +0.81 % |
|
| 2025-04-15 | -0.21 % |
|
| 2025-04-14 | +2.59 % |
|
| 2025-04-10 | -2.83 % |
|
| 2025-04-09 | +2.87 % |
|
| 2025-04-07 | -3.9 % |
|
| 2025-04-04 | -7.39 % |
|
| 2025-04-03 | +2.35 % |
|
| 2025-04-02 | -0.52 % |
|
| 2025-04-01 | -1.22 % |
|
| 2025-03-31 | -0.39 % |
|
| 2025-03-27 | +0.17 % |
|
| 2025-03-25 | -1.4 % |
|
| 2025-03-24 | -1.12 % |
|
| 2025-03-20 | +0.26 % |
- AstraZeneca (NASDAQ:AZN) stock saw a 0.26% increase due to significant increases in institutional investments, particularly by Independent Advisor Alliance and other firms, as well as a recent upgrade in ratings by analysts and an upcoming dividend payment.
- The AstraZeneca (AZN) stock saw a 0.26% increase due to optimistic developments in the oncology small molecule drugs market, where strategic investments and innovative treatments are expected to fuel growth, enhancing competitive advantages for leading pharmaceutical companies like AstraZeneca.
- AstraZeneca (AZN) stock increased by 0.26% last night, which may be attributed to positive trends in the biotechnology sector, as illustrated by competing companies like Cellectis and Achilles Therapeutics showing strong investment potential and institutional backing, which generally boosts investor sentiment towards related firms, including AstraZeneca.
- AstraZeneca's (AZN) stock increased by 0.26% following the announcement of promising data from HUTCHMED's SAVANNAH Phase II trial, demonstrating high and durable response rates for savolitinib combined with TAGRISSO® in treating MET-high lung cancer, which indicates a potential new effective treatment strategy in a challenging patient population.
|
| 2025-03-18 | -0.39 % |
|
| 2025-03-17 | -0.3 % |
|
| 2025-03-14 | +1.42 % |
|
| 2025-03-13 | +1.24 % |
|
| 2025-03-12 | +1.79 % |
|
| 2025-03-11 | -2.3 % |
|
| 2025-03-07 | +0.04 % |
|
| 2025-03-06 | -0.63 % |
|
| 2025-03-05 | +0.92 % |
|
| 2025-03-04 | +1.51 % |
|
| 2025-03-03 | -0.14 % |
|
| 2025-02-27 | +0.17 % |
|
| 2025-02-26 | +0.16 % |
|
| 2025-02-25 | +0.95 % |
|
| 2025-02-24 | +0.63 % |
|
| 2025-02-21 | +0.97 % |
|
| 2025-02-20 | +1.02 % |
|
| 2025-02-19 | -1.32 % |
|
| 2025-02-14 | -1.17 % |
|
| 2025-02-13 | +0.03 % |
- The article discusses the comparative investment potential of Compugen and Artiva Biotherapeutics, highlighting their market positions, institutional ownership, and analyst recommendations, while noting that AstraZeneca (AZN) stock was up by 0.03%. AstraZeneca's stock could be experiencing an increase due to favorable analyst sentiment or positive developments related to its collaborations and immuno-oncology products, which often generate investor confidence.
- AstraZeneca (NASDAQ: AZN) stock experienced a slight increase of 0.03% due to ongoing institutional interest and a favorable shift in analyst ratings, despite the company reporting lower-than-expected quarterly earnings.
- AstraZeneca's (NASDAQ:AZN) stock saw a slight increase of 0.03% due to positive actions from hedge funds that adjusted their positions, upgrades from analysts, and the announcement of a higher semi-annual dividend payout.
- AstraZeneca's (AZN) stock increased by 0.03% last night, potentially due to favorable market conditions or positive sentiment surrounding its collaborations and developments in the biopharmaceutical sector, particularly with companies like SpringWorks Therapeutics and Innate Pharma.
|
| 2025-02-12 | +2.34 % |
|
| 2025-02-11 | +0.1 % |
|
| 2025-02-10 | +0.93 % |
|
| 2025-02-07 | -0.51 % |
|
| 2025-02-06 | +2 % |
|
| 2025-02-05 | +2.86 % |
|
| 2025-02-04 | -1.29 % |
|
| 2025-02-03 | -1.27 % |
|
| 2025-01-31 | -0.67 % |
|
| 2025-01-30 | +1.41 % |
- AstraZeneca (AZN) stock rose by 1.41% due to ongoing class action lawsuits related to allegations of insurance fraud and legal issues in China, raising investor attention despite the potential risks highlighted by the complaints.
- AstraZeneca PLC (LON:AZN) stock rose by 1.41% after receiving a consensus "Moderate Buy" rating from analysts, with strong endorsements from several brokerages, which likely contributed to positive investor sentiment.
The stock's increase can be attributed to favorable analyst ratings, including "buy" recommendations and high price targets, as well as insider purchases, indicating confidence in the company's future performance.
- AstraZeneca (AZN) stock rose by 1.41% last night, likely influenced by positive market sentiment surrounding the upcoming 2025 budget and general economic trends that encourage investment.
- AstraZeneca (AZN) stock rose 1.41% amidst ongoing class action litigation related to alleged fraud and misstatements affecting the company’s operations and prospects in China, suggesting some investor confidence in a potential resolution or recovery.
- AstraZeneca's stock rose by 1.41% after Berenberg Bank reaffirmed a "buy" rating and set a price target, alongside positive ratings from several other analysts, indicating strong investor confidence in the company's prospects.
|
| 2025-01-29 | +0.95 % |
|
| 2025-01-28 | -0.7 % |
|
| 2025-01-27 | +1.48 % |
|
| 2025-01-24 | +0.67 % |
|
| 2025-01-23 | +0.59 % |
- AstraZeneca's stock (AZN) rose by 0.59% last night amidst news of an ongoing class action lawsuit related to prior misleading statements about the company's operations and legal troubles in China, likely indicating mixed investor sentiment following recent challenges.
The stock may have gone up due to potential positive reactions from investors regarding the class action lawsuit, as it opens opportunities for some shareholders to seek recovery for losses, coupled with general market movements or external factors that provided upward pressure.
- AstraZeneca (AZN) stock rose by 0.59% after investment analysts at Leerink Partners increased their FY2026 earnings per share estimates for the company, indicating positive sentiment and revised expectations for its financial performance.
- AstraZeneca PLC (AZN) stock rose by 0.59% after institutional investors, including Ameritas Advisory Services LLC, significantly increased their stakes in the company, reflecting strong investor confidence and recent positive earnings results that exceeded market expectations.
- AstraZeneca (AZN) stock saw a slight increase of 0.59%, likely influenced by positive investor sentiment surrounding its recent performance and the overall positive trends in the stock market on January 23, 2025.
- AstraZeneca (AZN) stock increased by 0.59% following a positive sentiment from institutional investors expanding their holdings and favorable upgrades from several analysts, indicating a strong buy interest in the company.
|
| 2025-01-22 | +0.35 % |
- AstraZeneca (NASDAQ:AZN) stock rose by 0.35% as several institutional investors, including Brooklyn Investment Group and Merit Financial Group, significantly increased their stakes in the company during the fourth quarter, reflecting positive investor sentiment and confidence in its financial performance and growth prospects.
- The article discusses class action lawsuits filed against various companies, including AstraZeneca (AZN), and mentions AZN's stock was up 0.35% last night. AstraZeneca's stock may have increased due to potential investor optimism or market sentiment, despite the allegations of legal issues, as such news may not have significantly impacted investor confidence at the moment.
- AstraZeneca's (AZN) stock rose 0.35% despite facing a tumultuous period marked by a 15% decline over six months due to investigations by Chinese regulators into alleged illegal drug imports and health fraud, as well as the arrest of key executives, which raised concerns about its market performance in China. The stock increase may be attributed to investors reacting to potential stabilization or optimism regarding the ongoing issues or corporate communications that suggest a path forward.
- AstraZeneca's stock rose 0.35% last night amidst a class action lawsuit investigation regarding allegations of misleading investors about its legal risks in China, leading to heightened scrutiny but potentially stabilizing investor sentiment for the time being.
|
| 2025-01-21 | +2.04 % |
|
| 2025-01-17 | -0.46 % |
|
| 2025-01-16 | +1.87 % |
|
| 2025-01-15 | +0.47 % |
|
| 2025-01-14 | -0.55 % |
|
| 2025-01-13 | -1.91 % |
|
| 2025-01-10 | +0.65 % |
|
| 2025-01-07 | -0.3 % |
|
| 2025-01-06 | +0.89 % |
|
| 2025-01-03 | +0.56 % |
|
| 2025-01-02 | +0.55 % |
|
| 2024-12-30 | -1.04 % |
|
| 2024-12-27 | -0.39 % |
|
| 2024-12-26 | +0.33 % |
|
| 2024-12-24 | -0.5 % |
|
| 2024-12-23 | +1.96 % |
|
| 2024-12-17 | +1.43 % |
|
| 2024-12-13 | -0.54 % |
|
| 2024-12-12 | -0.68 % |
|
| 2024-12-05 | +1.12 % |
|
| 2024-12-02 | -0.86 % |
|
| 2024-11-29 | +0.63 % |
|
| 2024-11-27 | +1.27 % |
|
| 2024-11-26 | -0.06 % |
|
| 2024-11-25 | +1.17 % |
|
| 2024-11-22 | +2.13 % |
|
| 2024-11-21 | +1.68 % |
|
| 2024-11-20 | -0.94 % |
|
| 2024-11-19 | +0.65 % |
|
| 2024-11-18 | +0.25 % |
|
| 2024-11-15 | -2.78 % |
- AstraZeneca Pharma India's Q2 2024 results showed significant revenue growth of 31.16% year-over-year to ₹408 crore, but a notable profit decline of 26.62% to ₹38.43 crore, primarily due to increased administrative expenses, leading to a -2.78% drop in its stock price. The stock decline can be attributed to the disappointing profit performance despite rising revenues, raising concerns among investors about the company's cost management.
- AstraZeneca (AZN) stock fell by 2.78% due to concerns in the healthcare sector following Robert F. Kennedy Jr.'s nomination as Secretary of Health and Human Services, given his controversial anti-vaccine stance and history of promoting misinformation about vaccines.
- AstraZeneca (NASDAQ: AZN) stock fell by 2.78% after recently announcing its earnings, despite exceeding earnings expectations, possibly impacted by mixed investor sentiment and broader market conditions.
- AstraZeneca's stock fell by 2.78% after Donald Trump appointed vaccine critic Robert F. Kennedy Jr., leading to concerns among investors about the potential impact on major pharmaceutical companies including AstraZeneca, Moderna, and GSK.
|
| 2024-11-14 | -0.38 % |
|
| 2024-11-13 | +0.15 % |
- AstraZeneca (AZN) stock rose by 0.15% amid broader market declines influenced by inflation concerns and foreign investor outflows, likely due to investors seeking relative stability in the pharmaceutical sector as other markets faced pressures.
- AstraZeneca (AZN) stock increased by 0.15% due to significant institutional investment activity, including new positions and increased holdings by various funds, along with favorable ratings and target price boosts from multiple research analysts.
- The article mentions that AstraZeneca (AZN) stock increased by 0.15% last night, although it does not provide specific reasons for this uptick; generally, stock prices can rise due to factors such as positive company news, favorable market conditions, or investor sentiment.
- AstraZeneca (AZN) stock rose by 0.15% amid overall market declines due to rising inflation concerns and foreign investor outflows, likely benefiting from company-specific developments or investor interest that remained positive despite broader market pressures.
The stock may have gone up due to factors such as positive news about product developments, strong earnings reports, or ongoing interest in healthcare stocks in light of market volatility.
|
| 2024-11-12 | +0.62 % |
|
| 2024-11-11 | +0.47 % |
- AstraZeneca (AZN) stock rose by 0.47% after JPMorgan reaffirmed its overweight rating with a price target of £140, alongside positive endorsements from other brokerages, reflecting strong confidence in the company's performance.
The stock's increase can be attributed to favorable analyst ratings and price targets from multiple financial institutions, suggesting strong market confidence in AstraZeneca's future growth potential.
- AstraZeneca (NASDAQ: AZN) stock rose by 0.47% as it prepares to announce its quarterly earnings, with analysts anticipating earnings of $1.02 per share, while recent analyst upgrades and positive ratings have also contributed to investor confidence.
- AstraZeneca (AZN) stock rose 0.47% as several hedge funds increased their stakes, with positive ratings adjustments from analysts indicating growing confidence in the company's prospects.
- AstraZeneca's stock (LON:AZN) rose by 0.47% following Shore Capital's reaffirmation of its buy rating, among other positive endorsements from several analysts, suggesting strong market confidence in the company's performance and prospects.
- AstraZeneca PLC (NASDAQ: AZN) stock rose 0.47% due to increased institutional investment, with firms like Assetmark Inc. growing their positions significantly, alongside positive analyst upgrades and strong market performance indicators.
|
| 2024-11-08 | -0.31 % |
|
| 2024-11-06 | -3.65 % |
|
| 2024-11-05 | -7.22 % |
|
| 2024-11-04 | +0.01 % |
|
| 2024-11-01 | +0.38 % |
|
| 2024-10-31 | -2.31 % |
|
| 2024-10-30 | -3.18 % |
|
| 2024-10-29 | -1.04 % |
|
| 2024-10-28 | +1.28 % |
|
| 2024-10-25 | -1.12 % |
- AstraZeneca (AZN) stock declined by 1.12% partly due to Deutsche Bank's downgrade of the stock from "hold" to "sell," despite some institutional investors increasing their stakes.
- AstraZeneca (AZN) stock experienced a decline of 1.12% due to investor sentiment possibly impacted by competition from emerging biotech companies like Innate Pharma and ProKidney, which offer stronger growth prospects and clinical advancements.
- AstraZeneca (AZN) stock declined by -1.12%, potentially due to concerns over the efficacy and future developments related to immunotherapy treatments for liver cancer, as highlighted in a recent study from the Johns Hopkins Kimmel Cancer Center that explored new aspects of immune response in hepatocellular carcinoma.
- AstraZeneca (AZN) stock fell by -1.12% due to a broader sell-off in the Indian equity markets, driven by unprecedented foreign fund outflows and a strong US dollar, which negatively impacted investor sentiment.
- AstraZeneca (AZN) stock declined by 1.12% amid reports of significant investment increases by International Assets Investment Management LLC, which raised its stake by 7,331.5% in the third quarter. The decline in stock may be attributed to market reactions to these investment activities, investors' profit-taking, or broader market trends rather than specific negative news regarding the company.
|
